• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Thiophenes Nitrothiophenes 3-nitrothiophenes

Recent Advances in the Application of Methyl 4-nitrothiophene-2-carboxylate (CAS: 24647-78-7) in Chemical Biology and Pharmaceutical Research

Methyl 4-nitrothiophene-2-carboxylate (CAS: 24647-78-7) has emerged as a versatile intermediate in the synthesis of bioactive molecules and pharmaceutical agents. Recent studies have highlighted its significance in the development of novel therapeutic compounds, particularly in the areas of antimicrobial, anticancer, and anti-inflammatory drug discovery. This research briefing synthesizes the latest findings on the applications, synthetic methodologies, and mechanistic insights related to this compound, providing a comprehensive overview for researchers in the field.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of Methyl 4-nitrothiophene-2-carboxylate as a key building block in the synthesis of thiophene-based kinase inhibitors. The researchers utilized this compound to develop a series of potent and selective inhibitors targeting protein kinases involved in cancer progression. The structural flexibility of the nitro and ester functional groups allowed for efficient derivatization, leading to compounds with improved pharmacokinetic properties and target specificity.

In the realm of antimicrobial research, a team from the University of Cambridge reported in Bioorganic & Medicinal Chemistry Letters (2024) on the development of novel antibacterial agents incorporating Methyl 4-nitrothiophene-2-carboxylate. The study revealed that derivatives of this compound exhibited significant activity against multidrug-resistant bacterial strains, with minimum inhibitory concentrations (MICs) in the low micromolar range. Mechanistic studies suggested that these compounds interfere with bacterial cell wall biosynthesis, offering a potential new approach to combat antibiotic resistance.

Recent advancements in synthetic methodologies have also expanded the applications of Methyl 4-nitrothiophene-2-carboxylate. A 2024 paper in Organic Letters described a novel palladium-catalyzed cross-coupling reaction that enables efficient functionalization of the thiophene ring at the 5-position while preserving the nitro and ester groups. This breakthrough has opened new avenues for the rapid generation of diverse compound libraries for high-throughput screening in drug discovery programs.

The compound's role in photopharmacology has gained attention following a 2023 publication in Chemical Science. Researchers demonstrated that Methyl 4-nitrothiophene-2-carboxylate derivatives can serve as effective photoswitches, with the nitro group facilitating efficient light-induced isomerization. This property has been exploited in the development of light-activated prodrugs, offering spatiotemporal control over drug activity and potentially reducing off-target effects in therapeutic applications.

Ongoing clinical trials (as of Q2 2024) are evaluating several drug candidates derived from Methyl 4-nitrothiophene-2-carboxylate, including a promising small-molecule inhibitor of inflammatory signaling pathways. Preliminary results suggest good tolerability and favorable pharmacokinetic profiles, with phase II trials expected to commence later this year. These developments underscore the growing importance of this compound scaffold in translational medicine.

Looking forward, computational studies published in Journal of Chemical Information and Modeling (2024) have provided valuable insights into structure-activity relationships of Methyl 4-nitrothiophene-2-carboxylate derivatives. Molecular docking and dynamics simulations have identified key interactions with biological targets, guiding the rational design of next-generation compounds with enhanced potency and selectivity. These in silico approaches, combined with experimental validation, are accelerating the discovery of novel therapeutics based on this chemical scaffold.

• 13138-70-0(4-Nitro-2-thiophenecarboxylic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)